Background Based on the results of randomized, double-blind, placebo-controlled trials, the
benefit and safety of edaravone in the treatment of amyotrophic lateral sclerosis remain …

Abstract Background and Objective The efficacy and safety of edaravone for the treatment of
amyotrophic lateral sclerosis (ALS) remain unclear. The aim of this meta-analysis was to …

Aim The study aims to increase understanding of edaravone's efficacy and safety as an
amyotrophic lateral sclerosis (ALS) treatment and provide significant insights regarding this …

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease that
affects the upper and lower motor neurons. Currently, the only treatment for ALS is riluzole …

Background In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS),
edaravone did not show a significant difference in the Revised ALS Functional Rating Scale …

Introduction Amyotrophic lateral sclerosis (ALS) is a progressive and incurable
neurodegenerative disease. While pharmacotherapy options remain limited, the Food and …

Our objective was to confirm the efficacy and safety of edaravone in amyotrophic lateral
sclerosis (ALS) patients. We conducted a 36-week confirmatory study, consisting of 12-week …

Background: There continues to be a need for new therapies to treat ALS. Objective: Provide
an overview of safety for edaravone in ALS patients during the first six cycles of treatment …

Following the first phase III study of edaravone for amyotrophic lateral sclerosis (ALS), this
extension study was performed to evaluate longer-term efficacy and safety. Patients given …

Abstract Background In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients
experienced significantly less physical functional decline with 24‐week edaravone vs …